Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018547 | 0.80 | ALDH1A1 (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL9622532 | 0.77 | ALDH1A1 (0.39) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL128446 | 0.77 | ALDH1A1 (0.39) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10699464 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5148345 | 0.74 | — | — | |
| SCHEMBL11077033 | 0.74 | — | — | |
| SCHEMBL693664 | 0.74 | MEN1 (0.37) | ALDH1A1 | |
| SCHEMBL1792016 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL193916 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6792934 | 0.71 | ALDH1A1 (0.62) | ALDH1A1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642567-B1 | Colouring composition comprising naphthoylene-benzimidazolium compound as direct dye, preparation and uses | OREAL (FR) | 2010-11-03 | — | — | EP | claimed |
| US-20060085923-A1 | Dye composition comprising a naphthoylene-benzimidazolium direct dye, process for dyeing keratin fibers and uses thereof | L'OREAL S.A. (FR) | 2006-04-27 | — | — | US | claimed |
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | PHARMACIA CORPORATION | 2005-04-07 | — | — | US | claimed |
| US-20060085923-A1 | Dye composition comprising a naphthoylene-benzimidazolium direct dye, process for dyeing keratin fibers and uses thereof | L'OREAL S.A. (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075374-A1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | MMP1, MMP2, MMP3 | ALDH1A1 925/4885KDM4E 1308/4885CYP1A2 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.